On March 28, 2025, Mangoceuticals converted 350 shares of Series B Convertible Preferred Stock into 256,666 shares of common stock, and on April 2, 2025, $500,000 of debt was converted into 333,333 shares of common stock, both at a conversion price of $1.50 per share.